Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer

被引：0
作者：
Im, Seock-Ah
Lee, Kyung-Hun
Min, Ahrum
Lee, Daewon
Kim, Tae Yong
Ryu, Han Suk
Koh, Jiwon
Cheon, Gi-Jeong
Shin, Yoon-Jung
Kim, Yujin
Moon, Hyeong-Gon
Han, Wonshik
Lee, Han-Byoel
Diolaiti, Morgan
Quigley, David
Ashworth, Alan
Cho, Nariya
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-PD15-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD15-08
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Targeting estrogen to kill ER-positive and ER-negative breast cancer
    Jordan, VC
    [J]. BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S4 - S4
  • [22] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
    Ueno, Takayuki
    [J]. CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [23] Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers
    Liu, Dingxie
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 95 - 105
  • [24] A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
    Mitri, Zahi Ibrahim
    Vuky, Jacqueline
    Kemmer, Kathleen A.
    Savin, Michael A.
    Parmar, Swapnil
    Kolodzie, Annette Kolodzie
    Johnson, Brett
    Williams-Belizaire, Rochelle
    Gray, Joe W.
    Mills, Gordon B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Axillary Response to Neoadjuvant Therapy in Node-Positive ER-Positive, HER2-Negative Breast Cancer
    Friedman-Eldar, Orli
    Ozmen, Tolga
    Reyes, Fernando Valle
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susane B.
    Moller, Mecker
    Franceschi, Dido
    Avisar, Eli
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S236 - S236
  • [26] Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers
    Dingxie Liu
    [J]. Breast Cancer Research and Treatment, 2020, 183 : 95 - 105
  • [27] The neoadjuvant endocrinetherapy vs chemotherapy in postmenopausal woment with ER-positive breast cancer
    Semiglazov, V. F.
    Semiglazov, V. V.
    Ivanov, V. G.
    Zhiltzova, E. R.
    Kletsel, A. E.
    Dashyan, G. A.
    Bozhok, A. A.
    Paltuev, R. M.
    Berstein, L. M.
    Krivorotko, R. V.
    [J]. BREAST, 2007, 16 : S50 - S50
  • [28] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    [J]. CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [29] AgNOR analysis of ER-positive and ER-negative tumor cells in breast cancer
    Guski, E
    Winzer, KJ
    Hufnagl, P
    Günther, L
    Kaufmann, O
    [J]. PROCEEDINGS OF THE GERMAN SOCIETY FOR PATHOLOGY 82ND MEETING - 1998: SOFT TISSUE TUMORS, 1998, : 470 - 470
  • [30] AgNOR analysis of ER-positive and ER-negative cells in breast cancer.
    Guski, H
    Winzer, KJ
    Hufnagl, P
    Gunther, L
    [J]. EUROPEAN JOURNAL OF HISTOCHEMISTRY, 1996, 40 (04): : 341 - 341
12345